27 сент. 2024 г. · In July 2024, Sanofi and Regeneron announced that the European Medicines Agency approved Dupixent as an add-on maintenance treatment for adults ...

3 июл. 2024 г. · The European Medicines Agency (EMA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive ...

27 сент. 2024 г. · The European Medicines Agency approved dupilumab as an add-on treatment for patients with COPD in July 2024, 1 and it was also approved earlier ...

27 сент. 2024 г. · With the label expansion, Dupixent becomes the first biologic treatment for COPD patients in the U.S. The IL-4 and IL-13 inhibitor is approved ...

27 сент. 2024 г. · In July 2024, Sanofi and Regeneron announced that the European Medicines Agency approved Dupixent as an add-on maintenance treatment for adults ...

27 сент. 2024 г. · On September 27, the US Food and Drug Administration (FDA) approved dupilumab (Dupixent, Sanofi/Regeneron) as an add-on maintenance treatment ...

31 мая 2024 г. · The FDA moved the target date for their decision on the dupilumab application by 3 months, citing a need for more efficacy data from its pivotal phase 3 trials.

27 сент. 2024 г. · The FDA approved it in September 2024 as an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic ...

5 июл. 2024 г. · The US Food and Drug Administration (FDA) pushed back its decision by three months, with a revised target action date of 27 September 2024. The ...